ArticleMultiple sclerosis journal - experimental, translational and clinical
Ocular-motor conduction dynamics and variability in multiple sclerosis-related internuclear ophthalmoparesis: A randomized dalfampridine trial.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Internuclear ophthalmoparesis (INO) in multiple sclerosis (MS) reflects impaired signal transmission within the medial longitudinal fasciculus (MLF). Increased pulse size ratio (PSR) and prolonged pulse time delay (PTD) quantify interocular velocity asymmetry and transmission timing. Objective: To characterize PSR and PTD during ocular-motor fatigue in MS-related INO and the effects of dalfampridine. Methods: In a randomized, double-blind, placebo-controlled crossover trial, 19 participants with MS-related INO underwent eye-movement recordings during a 10-min saccadic task. PSR and PTD were analyzed at saccade, INO, and participant levels. Results: 23,904 INO and 2408 control paired saccades were analyzed. In INO, PTD was prolonged and PSR elevated, with a positive correlation. Dalfampridine did not significantly improve prespecified ocular-motor outcomes, including mean PSR, mean PTD, or early-late fatigue measures. Responses were heterogeneous. Exploratory analyses showed dynamic PSR and PTD fluctuations, with a trend toward reduced PSR variability during dalfampridine. Greater trough PTD variability was associated with larger PTD shortening during dalfampridine, but not placebo. Conclusions: Dalfampridine did not significantly improve prespecified ocular-motor outcomes. PSR and PTD capture complementary aspects of internuclear signal transmission, with ocular-motor fatigue reflecting dynamic instability. PTD variability is associated with variation in response to dalfampridine, supporting further study as a tract-specific biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.